J. Montero, B. Kilian, J. Chan, P. Bayliss, and C. Heisenberg, Phosphoinositide 3-Kinase Is Required for Process Outgrowth and Cell Polarization of Gastrulating Mesendodermal Cells, Current Biology, vol.13, issue.15, pp.1279-89, 2003.
DOI : 10.1016/S0960-9822(03)00505-0

X. Yang, H. Chrisman, and C. Weijer, PDGF signalling controls the migration of mesoderm cells during chick gastrulation by regulating N-cadherin expression, Development, vol.135, issue.21, pp.3521-3551, 2008.
DOI : 10.1242/dev.023416

C. Yeh, Y. Liu, C. Chang, S. Lai, C. Hsiao et al., Ptenb Mediates Gastrulation Cell Movements via Cdc42/AKT1 in Zebrafish, PLoS ONE, vol.348, issue.Pt 1, p.18702, 2011.
DOI : 10.1371/journal.pone.0018702.s006

S. Grille, A. Bellacosa, J. Upson, A. Klein-szanto, F. Van-roy et al., The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines, Cancer Res, vol.63, issue.9, pp.2172-2180, 2003.

B. Govindarajan, J. Sligh, B. Vincent, M. Li, J. Canter et al., Overexpression of Akt converts radial growth melanoma to vertical growth melanoma, Journal of Clinical Investigation, vol.117, issue.3, pp.719-748, 2007.
DOI : 10.1172/JCI30102DS1

H. Tang, D. Massi, B. Hemmings, M. Mandala, Z. Hu et al., AKT-ions with a TWIST between EMT and MET, Oncotarget, vol.7, issue.38, pp.62767-77, 2016.
DOI : 10.18632/oncotarget.11232

P. Liu, H. Cheng, T. Roberts, and J. Zhao, Targeting the phosphoinositide 3-kinase pathway in cancer, Nature Reviews Drug Discovery, vol.3, issue.8, pp.627-671, 2009.
DOI : 10.4049/jimmunol.175.5.2783

R. Ramanathan, S. Mcdonough, H. Kennecke, S. Iqbal, J. Baranda et al., Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005), Cancer, vol.11, issue.13, pp.2193-2200, 2015.
DOI : 10.1586/era.10.226

B. Ma, B. Goh, W. Lim, E. Hui, E. Tan et al., Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079), Investigational New Drugs, vol.20, issue.22, pp.985-91, 2015.
DOI : 10.1158/1078-0432.CCR-14-0868

D. Ahn, J. Li, L. Wei, A. Doyle, J. Marshall et al., Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer, Scientific Reports, vol.109, issue.1, p.12122, 2015.
DOI : 10.1073/pnas.1204384109

Y. Oki, M. Fanale, J. Romaguera, L. Fayad, N. Fowler et al., Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma, British Journal of Haematology, vol.116, issue.4, pp.463-70, 2015.
DOI : 10.1038/onc.2008.245

T. Yap, L. Yan, A. Patnaik, I. Fearen, D. Olmos et al., First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors, Journal of Clinical Oncology, vol.29, issue.35, pp.4688-95, 2011.
DOI : 10.1200/JCO.2011.35.5263

C. Hudis, C. Swanton, Y. Janjigian, R. Lee, S. Sutherland et al., A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors, Breast Cancer Research, vol.30, issue.6, p.110, 2013.
DOI : 10.1200/JCO.2011.35.6725

I. Brana, R. Berger, T. Golan, P. Haluska, J. Edenfield et al., A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours, British Journal of Cancer, vol.111, issue.10, pp.1932-1976, 2014.
DOI : 10.5966/sctm.2012-0096

M. Fouladi, J. Perentesis, C. Phillips, S. Leary, J. Reid et al., A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study, Pediatric Blood & Cancer, vol.59, issue.7, pp.1246-51, 2014.
DOI : 10.1002/pbc.23412

F. Janku, D. Hong, S. Fu, S. Piha-paul, A. Naing et al., Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors, Cell Reports, vol.6, issue.2, pp.377-87, 2014.
DOI : 10.1016/j.celrep.2013.12.035

M. Konopleva, R. Walter, S. Faderl, E. Jabbour, Z. Zeng et al., Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia, Clinical Cancer Research, vol.20, issue.8, pp.2226-2261, 2014.
DOI : 10.1158/1078-0432.CCR-13-1978

L. Molife, L. Yan, J. Vitfell-rasmussen, A. Zernhelt, D. Sullivan et al., Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors, Journal of Hematology & Oncology, vol.7, issue.1, 2014.
DOI : 10.1158/1078-0432.CCR-08-0125

B. Davies, N. Guan, A. Logie, C. Crafter, L. Hanson et al., Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors, Molecular Cancer Therapeutics, vol.14, issue.11, pp.2441-51, 2015.
DOI : 10.1158/1535-7163.MCT-15-0230

K. Do, G. Speranza, R. Bishop, S. Khin, L. Rubinstein et al., Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer, Investigational New Drugs, vol.13, issue.12, pp.720-728, 2015.
DOI : 10.2174/138945012803530062

T. Doi, K. Tamura, Y. Tanabe, K. Yonemori, T. Yoshino et al., Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, vol.1, issue.3, pp.409-425, 2015.
DOI : 10.1158/2159-8274.CD-10-0010

A. Gonzalez-angulo, I. Krop, A. Akcakanat, H. Chen, S. Liu et al., SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer, JNCI: Journal of the National Cancer Institute, vol.19, issue.19, 2015.
DOI : 10.1158/1078-0432.CCR-13-0884

S. Gupta, G. Argiles, P. Munster, A. Hollebecque, O. Dajani et al., A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies, Clinical Cancer Research, vol.21, issue.23, pp.5235-5279, 2015.
DOI : 10.1158/1078-0432.CCR-15-0180

V. Chung, S. Mcdonough, P. Philip, D. Cardin, A. Wang-gillam et al., Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy, JAMA Oncology, vol.3, issue.4, pp.516-538, 2017.
DOI : 10.1001/jamaoncol.2016.5383

M. Arboleda, J. Lyons, F. Kabbinavar, M. Bray, B. Snow et al., Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells, Cancer Res, vol.63, issue.1, pp.196-206, 2003.

R. Dillon, R. Marcotte, B. Hennessy, J. Woodgett, G. Mills et al., Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression, Cancer Research, vol.69, issue.12, pp.5057-64, 2009.
DOI : 10.1158/0008-5472.CAN-08-4287

J. Hutchinson, J. J. Cardiff, R. Woodgett, J. Muller, and W. , Activation of Akt-1 (PKB-??) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion, Cancer Research, vol.64, issue.9, pp.3171-3179, 2004.
DOI : 10.1158/0008-5472.CAN-03-3465

H. Irie, R. Pearline, D. Grueneberg, M. Hsia, P. Ravichandran et al., Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial???mesenchymal transition, The Journal of Cell Biology, vol.267, issue.6, pp.1023-1057, 2005.
DOI : 10.1126/science.286.5445.1741

C. Li, W. Xia, S. Lim, J. Hsu, L. Huo et al., AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation, Cancer Research, vol.76, issue.6, pp.1451-62, 2016.
DOI : 10.1158/0008-5472.CAN-15-1941

M. Riggio, M. Perrone, M. Polo, M. Rodriguez, M. May et al., AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci Rep, p.44244, 2017.

J. Gioanni, J. Fischel, J. Lambert, F. Demard, C. Mazeau et al., Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: Establishment, characterization and response to cytotoxic treatment, European Journal of Cancer and Clinical Oncology, vol.24, issue.9, pp.1445-55, 1988.
DOI : 10.1016/0277-5379(88)90335-5

I. Giaever and C. Keese, A morphological biosensor for mammalian cells, Nature, vol.366, issue.6455, pp.591-593, 1993.
DOI : 10.1038/366591a0

C. Porta, C. Paglino, and A. Mosca, Targeting PI3K/Akt/mTOR Signaling in Cancer, Frontiers in Oncology, vol.13, issue.Suppl 1, p.64, 2014.
DOI : 10.1016/j.drup.2009.12.001

K. Wong, J. Engelman, and L. Cantley, Targeting the PI3K signaling pathway in cancer, Current Opinion in Genetics & Development, vol.20, issue.1, pp.87-90, 2010.
DOI : 10.1016/j.gde.2009.11.002

M. Barzegar, S. Ma, C. Zhang, X. Chen, Y. Gu et al., SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling, British Journal of Cancer, vol.9, issue.8, pp.1154-63, 2017.
DOI : 10.1002/ijc.25255

Y. Benhamou, V. Picco, H. Raybaud, A. Sudaka, E. Chamorey et al., Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma, Oncotarget, vol.7, issue.28, pp.44236-51, 2016.
DOI : 10.18632/oncotarget.10005

I. Maroulakou, W. Oemler, S. Naber, and P. Tsichlis, Akt1 Ablation Inhibits, whereas Akt2 Ablation Accelerates, the Development of Mammary Adenocarcinomas in Mouse Mammary Tumor Virus (MMTV)-ErbB2/Neu and MMTV-Polyoma Middle T Transgenic Mice, Cancer Research, vol.67, issue.1, pp.167-77, 2007.
DOI : 10.1158/0008-5472.CAN-06-3782

F. Martins, S. De-sousa, D. Santos, E. Woo, S. Gallottini et al., PI3K-AKT-mTOR pathway proteins are differently expressed in oral carcinogenesis, Journal of Oral Pathology & Medicine, vol.44, issue.10, pp.746-52, 2016.
DOI : 10.1016/j.oraloncology.2007.08.006

J. Grandis and . Hd, El-Naggar AK, and The Cancer Genome Atlas Group Comprehensive genomic characterization of squamous cell carcinoma of the head and neck. TCGA 2nd annual scientific symposium, 2012.

D. Simpson, L. Mell, and E. Cohen, Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck, Oral Oncology, vol.51, issue.4, pp.291-299, 2015.
DOI : 10.1016/j.oraloncology.2014.11.012

S. Hehlgans, I. Eke, and N. Cordes, Targeting FAK Radiosensitizes 3-Dimensional Grown Human HNSCC Cells Through Reduced Akt1 and MEK1/2 Signaling, International Journal of Radiation Oncology*Biology*Physics, vol.83, issue.5, pp.669-76, 2012.
DOI : 10.1016/j.ijrobp.2012.01.065

H. Stegeman, P. Span, W. Peeters, M. Verheijen, R. Grenman et al., Interaction between hypoxia, p.1

, signaling in HNSCC and NSCLC: implications for future treatment strategies, Future science OA, vol.2, issue.1, p.84, 2016.

R. Silva-oliveira, M. Melendez, O. Martinho, M. Zanon, L. De-souza-viana et al., AKT can modulate the <i>in vitro</i> response of HNSCC cells to irreversible EGFR inhibitors, Oncotarget, vol.8, issue.32, pp.53288-301, 2017.
DOI : 10.18632/oncotarget.18395

Y. Cheng, Y. Wang, J. Li, I. Chang, and C. Wang, A novel read-through transcript <i>JMJD7-PLA2G4B</i> regulates head and neck squamous cell carcinoma cell proliferation and survival, Oncotarget, vol.8, issue.2, pp.1972-82, 2017.
DOI : 10.18632/oncotarget.14081

J. Chang, S. Jung, J. Kim, G. Shim, H. Park et al., Carboxyl-Terminal Modulator Protein Positively Acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via Regulating Akt phosphorylation, Scientific Reports, vol.71, issue.1, p.28503, 2016.
DOI : 10.1158/0008-5472.CAN-11-0128

M. Fury, E. Sherman, S. Haque, S. Korte, D. Lisa et al., A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, vol.14, issue.Suppl 14, pp.591-599, 2012.
DOI : 10.1158/1078-0432.CCR-07-0955

M. Fury, N. Lee, E. Sherman, A. Ho, S. Rao et al., A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.87, issue.3, pp.479-86, 2013.
DOI : 10.1016/j.ijrobp.2013.06.2043

M. Fury, E. Sherman, A. Ho, H. Xiao, F. Tsai et al., A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer, Cancer, vol.30, issue.suppl, pp.1823-1854, 2013.
DOI : 10.1128/JVI.00487-12

G. Nitulescu, D. Margina, P. Juzenas, Q. Peng, O. Olaru et al., Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review), International Journal of Oncology, vol.48, issue.3, pp.869-85, 2016.
DOI : 10.3892/ijo.2015.3306

H. Gong, M. Liu, J. Klomp, B. Merrill, J. Rehman et al., Method for Dual Viral Vector Mediated CRISPR-Cas9 Gene Disruption in Primary Human Endothelial Cells, Scientific Reports, vol.5, issue.1, p.42127, 2017.
DOI : 10.1093/nar/gkm407

L. Ochoa-callejero, A. Pozo-rodrigalvarez, R. Martinez-murillo, and A. Martinez, Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and more brain damage, Scientific Reports, vol.70, issue.1, p.33495, 2016.
DOI : 10.1016/S0024-3205(01)01454-0

S. Millis, S. Ikeda, S. Reddy, Z. Gatalica, and R. Kurzrock, Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19???784 Diverse Solid Tumors, JAMA Oncology, vol.2, issue.12, pp.1565-73, 2016.
DOI : 10.1001/jamaoncol.2016.0891

H. Li, J. Wawrose, W. Gooding, L. Garraway, V. Lui et al., Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Molecular cancer research : MCR, pp.571-82, 2014.